Cardiovascular Video Recap—October 23, 2025

This biweekly video brings you key highlights from across the cardiovascular landscape, featuring the latest data releases, company updates, and research milestones.

Watch Our Video Summary Capturing Top Cardiovascular News from the Last Two Weeks

Top Stories Covered in This Video

💵 Jupiter Endovascular Secures $40M for TFX Platform Development [1] [US • 08 Oct 2025]

https://cardiovascularnews.com/jupiter-endovascular-secures-funds-to-continue-development-of-tfx-platform/
Context: Jupiter Endovascular closes Series B financing to continue the development of its Transforming Fixation (TFX) platform and complete the SPIRARE II clinical trial.
Key point: The Vertex catheter with TFX technology has received FDA clearance and is progressing to pivotal trials for pulmonary embolism treatment.
Implication: This breakthrough technology may revolutionize endovascular medicine by providing more stability and control in complex cardiovascular interventions.

❤️ Milestone Pharmaceuticals to Present Etripamil Data at AHA 2025 [2] [US • 09 Oct 2025]

https://investors.milestonepharma.com/news-releases/news-release-details/milestoner-pharmaceuticals-present-data-etripamil-american-heart
Context: Milestone Pharmaceuticals will present data on etripamil for PSVT at the American Heart Association (AHA) Scientific Sessions.
Key point: The study highlights the efficacy, safety, and tolerability of self-administered etripamil for treating paroxysmal supraventricular tachycardia.
Implication: The presentation could further establish etripamil as a critical treatment option for patients with acute PSVT.

🧬 Vasa Therapeutics Receives FDA IND Clearance for VS-041 in HFpEF [3] [US • 13 Oct 2025]

https://firstwordpharma.com/story/6320981
Context: Vasa Therapeutics has received FDA clearance to advance VS-041, a small molecule inhibitor, for treating heart failure with preserved ejection fraction (HFpEF).
Key point: The Phase 1c clinical trial will evaluate VS-041’s safety and its potential impact on biomarkers like endotrophin.
Implication: VS-041 could offer a much-needed disease-modifying treatment for HFpEF, which currently lacks effective therapies.

🫀 EACTS 2025 Presents New Data on Aortic Arch Remodeling Device [4] [EU • 14 Oct 2025]

https://cardiovascularnews.com/eacts-2025-hears-new-data-on-aortic-arch-remodelling-device/
Context: Data from the AMDS PERSEVERE and PROTECT trials show positive clinical outcomes for the Ascyrus medical dissection stent (AMDS) in treating acute aortic dissections.
Key point: The results show a high resolution of visceral and renal malperfusion, with significant improvement in patient outcomes.
Implication: The AMDS stent could be a game-changer for patients with complicated aortic dissections, offering improved survival and fewer complications.

🤝 Healthium Medtech Partners with Tisgenx to Strengthen Cardiac Care Portfolio [5] [India • 15 Oct 2025]

https://www.expresshealthcare.in/amp/news/healthium-medtech-partners-with-tisgenx-to-strengthen-cardiac-care-portfolio/451151/
Context: Healthium Medtech partners with Tisgenx to distribute bovine pericardial tissue patches in India.
Key point: These patches are essential for valve repair and complex cardiovascular procedures.
Implication: This partnership expands Healthium’s offerings in cardiac care, addressing the growing demand for advanced surgical products in India.

🤖 Hello Heart Launches AI Assistant for Medication Management [6] [US • 14 Oct 2025]

https://www.fiercehealthcare.com/health-tech/hello-heart-adds-medication-management-tools
Context: Hello Heart introduces Nia, an AI assistant to improve medication adherence for heart disease patients.
Key point: Nia helps patients track medications, blood pressure, and cholesterol, while providing medication reminders and health insights.
Implication: This AI-driven approach could reduce hospitalizations and healthcare costs by improving medication adherence and patient engagement.

🔄 Enrolment Completed in CONFORM Pivotal Trial of LAAO System [7] [EU • 15 Oct 2025]

https://cardiovascularnews.com/enrolment-completed-in-conform-pivotal-trial-of-laao-system/
Context: Conformal Medical completes patient enrollment in the CONFORM pivotal trial of the CLAAS AcuFORM LAAO device for stroke prevention in AF patients.
Key point: The system simplifies procedures by conforming to patient anatomy, aiming to improve outcomes for those with non-valvular atrial fibrillation.
Implication: This trial could lead to wider adoption of LAAO devices, providing better stroke prevention options for atrial fibrillation patients.

💊 FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes [8] [US • 20 Oct 2025]

https://www.ajmc.com/view/fda-expands-semaglutide-label-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes
Context: The FDA expands the indication for oral semaglutide (Rybelsus) to reduce cardiovascular risk in adults with type 2 diabetes.
Key point: This marks the first oral GLP-1 receptor agonist approved for cardiovascular risk reduction, based on the SOUL trial.
Implication: This approval provides a new therapeutic option for diabetes patients at risk of cardiovascular events, broadening treatment options beyond blood sugar control.

Why it matters

Innovative cardiovascular technologies are advancing, from new drug treatments [8] to device innovations in aortic dissection [4] and stroke prevention [7].
AI and digital health are transforming patient management, with Hello Heart’s AI assistant aiming to tackle medication adherence [6].
Partnerships like the one between Healthium and Tisgenx are expanding access to critical cardiac solutions in emerging markets like India [5].
New developments in heart failure treatments [3] and pivotal trials [7] are setting the stage for more targeted, effective interventions for patients.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What’s the significance of Jupiter Endovascular’s Series B financing?

The funding will support the SPIRARE II trial and commercialization of the Vertex catheter with TFX technology, which could revolutionize endovascular procedures by offering greater stability and control [1].

How could Milestone Pharmaceuticals’ data impact PSVT treatment?

Etripamil’s safety and efficacy data presented at AHA 2025 could help position it as a key therapy for patients with paroxysmal supraventricular tachycardia [2].

What does the FDA approval for semaglutide mean for cardiovascular patients with diabetes?

Semaglutide’s expanded label for cardiovascular risk reduction offers a significant new option for patients with type 2 diabetes, particularly those at high cardiovascular risk [8].

What makes the AMDS stent a breakthrough for aortic dissections?

The AMDS stent’s ability to treat complex aortic dissections, especially in patients with visceral and renal malperfusion, marks a significant advancement in the treatment of this high-risk condition [4].

Entities / Keywords

Jupiter Endovascular; TFX platform; Vertex catheter; pulmonary embolism • Milestone Pharmaceuticals; etripamil; PSVT; AHA 2025 • Vasa Therapeutics; VS-041; HFpEF; endotrophin • Artivion; Ascyrus medical dissection stent; AMDS; aortic dissection • Healthium Medtech; Tisgenx; pericardial tissue patches; cardiac care • Hello Heart; AI medication management; hypertension; heart disease • Conformal Medical; CLAAS AcuFORM; LAAO device; stroke prevention • Semaglutide; cardiovascular risk; type 2 diabetes; FDA approval.